Latest Headlines

Latest Headlines

Medigene files to raise €50M to hit gas on T-cell R&D programs

Medigene is preparing to ratchet up investment in T-cell receptor (TCR) R&D programs. The plan is to raise up to €50 million ($56 million), funnel the cash into R&D programs and create a pipeline of up to 10 TCRs.

Medigene gambles on dendritic cell cancer vaccines in Trianta buyout

Germany's Medigene AG has nabbed a small cancer vaccine developer in a buyout which will add a team of investigators from one of the country's top research institutes. Medigene agreed to pay about 4 million euros in stock for Trianta Immunotherapies, with another 6 million euro chunk held aside for possible milestone payments.

MediGene, Johns Hopkins join on HPV vax research

MediGene, a Martinsried/Munich-based biotech, and The Johns Hopkins University will work together to create HPV vaccine candidates using the German firm's AAVLP platform. The preclinical program uses

Medigene forms spin-off Immunocore

German biotech MediGene announced today that its UK subsidiary, MediGene Ltd., will be merged into its new spin-off company, Immunocore. As of today, the new company--financed by MediGene and three

MediGene sells European rights to Oracea

MediGene has sold the European rights to Oracea for rosacea to Galderma Laboratories for €8 million upfront and up to €32 million in total based on certain commercialization milestones.

Unexpected death brings MediGene Phase I to a halt

MediGene AG placed a clinical hold on the trial of an experimental therapy for rheumatoid arthritis after a paid subject in the Phase I study- a healthy father of three-- died unexpectedly in

Pfizer rumored to be eyeing MediGene buyout

Rumors are swirling that Pfizer is looking to take over the German biotech

Rumor Mill: Pfizer eyeing MediGene

Rumors are swirling that Pfizer is looking to take over the German biotech